Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.46 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.46 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965129 | 0.98 | CHRM2 (0.47) | ALDH1A1CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL7266907 | 0.89 | CHRM1 (0.49) | CHRM2CHRM1CHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL11442910 | 0.87 | ALDH1A1 (0.40) | ALDH1A1CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL10369501 | 0.87 | CHRM1 (0.51) | CHRM2CHRM1CHRM4CHRM3 | |
| Oxalic Acid SCHEMBL10367531 | 0.84 | CHRM1 (0.45) | CHRM2CHRM1CHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL4322280 | 0.81 | ALDH1A1 (0.45) | ALDH1A1CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL3314224 | 0.78 | CHRM1 (0.40) | CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL9696817 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CHRM2CHRM1CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL9444152 | 0.78 | ALDH1A1 (0.53) | ALDH1A1CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL8872327 | 0.77 | SLC6A2 (0.36) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-5686463-A | Oxadiazoles useful in the treatment of senile dementia | MERCK, SHARP & DOHME, LTD. (GB) | 1997-11-11 | — | — | US | disclosed |
| EP-0239309-B1 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME (GB) | 1994-01-12 | — | — | EP | disclosed |
| US-5262427-A | Cognition activators for Alzheimer*s disease | NOVO NORDISK A/S (DK) | 1993-11-16 | — | — | US | disclosed |
| US-5073557-A | Cognition activators, stimulants of central muscarinic acetylc holine receptors | MERCK SHARP & DOHME LIMITED (GB) | 1991-12-17 | — | — | US | disclosed |
| EP-0416754-A2 | A novel substituted pyrazine, formulations thereof and use in medicine | MERCK SHARP & DOHME LTD. (GB) | 1991-03-13 | — | — | EP | disclosed |
| US-4925942-A | Preparation of quinuclidine-3-methanol | RUTGERSWERKE AG (DE) | 1990-05-15 | — | — | US | disclosed |
| EP-0239309-A2 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1987-09-30 | — | — | EP | disclosed |
| US-4525475-A | Prevention of thrombolic disorder with imidazole derivatives and salts thereof | THOROGOOD PETER B (GB) | 1985-06-25 | — | — | US | disclosed |
| EP-0015002-B1 | 1-SUBSTITUTED IMIDAZOLES, AND SALTS THEREOF, A METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-04-18 | — | — | EP | disclosed |
| US-4328234-A | Imidazole derivatives and salts thereof and pharmaceutical formulations useful in thrombo-embolic disorders | BURROUGHS WELLCOME CO. (US) | 1982-05-04 | — | — | US | disclosed |
| EP-0015002-A1 | 1-substituted imidazoles, and salts thereof, a method for their preparation and pharmaceutical formulations thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | GRIN1, PARK7, GRIN3A | CHRM2 518/4885CHRM1 80/4885CHRM4 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.